Cardiology Doctors Medicine Trials 
Velocity Clinical Research
MARCH 7, 2024
It’s easy to hear the enthusiasm for clinical trials when William Cromwell, MD, FAHA, FNLA , Principal Investigator and a leader of the Velocity Cardiometabolic CARE Council , discusses their importance to patients yesterday, today, and tomorrow. You can also do that by researching, publishing and teaching.
Velocity Clinical Research
DECEMBER 6, 2023
In addition to being one of Poland’s top recruiting sites in cardiology trials, ClinMedica also recruits patients across a broad range of therapeutic areas involving ambulatory medicine. About Velocity Clinical Research Velocity is the leading integrated site organization for clinical trials. and Europe.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Velocity Clinical Research
JANUARY 3, 2024
The acquisition of KO-MED is Velocity’s first foray into Oncology research, which accounts for roughly 40-50% of clinical trials globally. In most cases, the participant of a clinical trial benefits from taking part, which is of great importance, especially in oncological trials.
pharmaphorum
NOVEMBER 16, 2020
Dr Jan Westerink, assistant professor of internal medicine, University Medical Center, Utrecht, believes that one issue is that the guidelines for addressing cardiovascular risk are too rigid, and don’t take into account each patient’s individual circumstance. The only problem at the moment is that it’s not what doctors are taught to do.
The Pharma Data
NOVEMBER 4, 2020
ULTOMIRIS is a prescription medicine used to treat: adults with a disease called Paroxysmal Nocturnal Hemoglobinuria (PNH). ULTOMIRIS is a medicine that affects your immune system and can lower the ability of your immune system to fight infections. Your doctor will decide if you need additional vaccination. INDICATIONS.
The Pharma Data
JULY 8, 2021
When added to the EMPEROR-Reduced trial results, these findings demonstrate Jardiance’s efficacy in all forms of heart failure regardless of ejection fraction. vice president, Clinical Development & Medical Affairs, Cardio-Metabolism & Respiratory Medicine, Boehringer Ingelheim Pharmaceuticals, Inc.
The Pharma Data
NOVEMBER 4, 2020
Progressed European regulatory review and commercial preparations : Continued to support regulatory review of VASCEPA by the European Medicines Agency (EMA) with the expectation of an early 2021 approval of VASCEPA for commercial sale in Europe. Thero, president and chief executive officer. “We
Expert insights. Personalized for you.
52 
Let's personalize your content